List of Tables
    Table 1. Multiple Sclerosis (MS) Drugs CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
    Table 2. Multiple Sclerosis (MS) Drugs Market Trends
    Table 3. Multiple Sclerosis (MS) Drugs Market Drivers
    Table 4. Multiple Sclerosis (MS) Drugs Market Challenges
    Table 5. Multiple Sclerosis (MS) Drugs Market Restraints
    Table 6. Global Multiple Sclerosis (MS) Drugs Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Multiple Sclerosis (MS) Drugs Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Multiple Sclerosis (MS) Drugs Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Multiple Sclerosis (MS) Drugs Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Multiple Sclerosis (MS) Drugs Manufacturers in Global Market, Ranking by Revenue (2021)
    Table 11. Global Multiple Sclerosis (MS) Drugs Revenue by Manufacturer, (US$ Million), 2017-2022
    Table 12. Global Multiple Sclerosis (MS) Drugs Revenue Share by Manufacturer, 2017-2022
    Table 13. Global Multiple Sclerosis (MS) Drugs Sales by Manufacturer, (K Pcs), 2017-2022
    Table 14. Global Multiple Sclerosis (MS) Drugs Sales Share by Manufacturer, 2017-2022
    Table 15. Global Multiple Sclerosis (MS) Drugs Price by Manufacturer (2017-2022) & (USD/Pcs)
    Table 16. Global Multiple Sclerosis (MS) Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 17. Global Multiple Sclerosis (MS) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Multiple Sclerosis (MS) Drugs as of 2021)
    Table 18. Top Players of Multiple Sclerosis (MS) Drugs in Global Market, Headquarters and Distribution of Producing Region
    Table 19. Manufacturers Multiple Sclerosis (MS) Drugs Product Type
    Table 20. Date of International Manufacturers Enter into Multiple Sclerosis (MS) Drugs Market
    Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 22. Top Multiple Sclerosis (MS) Drugs Players in United States Market, Ranking by Revenue (2021)
    Table 23. United States Multiple Sclerosis (MS) Drugs Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 24. United States Multiple Sclerosis (MS) Drugs Revenue Share by Players, 2020, 2021 & 2022
    Table 25. United States Multiple Sclerosis (MS) Drugs Sales by Players, (K Pcs), 2020, 2021 & 2022
    Table 26. United States Multiple Sclerosis (MS) Drugs Sales Share by Players, 2020, 2021 & 2022
    Table 27. Global Multiple Sclerosis (MS) Drugs Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 28. Global Multiple Sclerosis (MS) Drugs Sales in Volume by Region (2017-2022) & (K Pcs)
    Table 29. Global Multiple Sclerosis (MS) Drugs Sales in Volume Forecast by Region (2023-2028) & (K Pcs)
    Table 30. Global Multiple Sclerosis (MS) Drugs Sales in Value by Region (2017-2022) & (US$ Million)
    Table 31. Global Multiple Sclerosis (MS) Drugs Sales in Value Forecast by Region (2023-2028) & (US$ Million)
    Table 32. North America Multiple Sclerosis (MS) Drugs Sales in Volume by Country (2017-2028) & (K Pcs)
    Table 33. North America Multiple Sclerosis (MS) Drugs Sales in Value by Country (2017-2028) & (US$ Million)
    Table 34. Asia Pacific Multiple Sclerosis (MS) Drugs Sales in Volume by Region (2017-2028) & (K Pcs)
    Table 35. Asia Pacific Multiple Sclerosis (MS) Drugs Sales in Value by Region (2017-2028) & (US$ Million)
    Table 36. Europe Multiple Sclerosis (MS) Drugs Sales in Volume by Country (2017-2028) & (K Pcs)
    Table 37. Europe Multiple Sclerosis (MS) Drugs Sales in Value by Country (2017-2028) & (US$ Million)
    Table 38. Latin America Multiple Sclerosis (MS) Drugs Sales in Volume by Country (2017-2028) & (K Pcs)
    Table 39. Latin Americaa Multiple Sclerosis (MS) Drugs Sales in Value by Country (2017-2028) & (US$ Million)
    Table 40. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales in Volume by Country (2017-2028) & (K Pcs)
    Table 41. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales in Value by Country (2017-2028) & (US$ Million)
    Table 42. Bayer AG Corporation Information
    Table 43. Bayer AG Description and Business Overview
    Table 44. Bayer AG Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 45. Bayer AG Multiple Sclerosis (MS) Drugs Product
    Table 46. Bayer AG Recent Development
    Table 47. Bayhill Therapeutics Corporation Information
    Table 48. Bayhill Therapeutics Description and Business Overview
    Table 49. Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 50. Bayhill Therapeutics Product
    Table 51. Bayhill Therapeutics Recent Development
    Table 52. Biogen Idec Corporation Information
    Table 53. Biogen Idec Description and Business Overview
    Table 54. Biogen Idec Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 55. Biogen Idec Product
    Table 56. Biogen Idec Recent Development
    Table 57. Cinnagen Corporation Information
    Table 58. Cinnagen Description and Business Overview
    Table 59. Cinnagen Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 60. Cinnagen Product
    Table 61. Cinnagen Recent Development
    Table 62. Daiichi Sankyo Corporation Information
    Table 63. Daiichi Sankyo Description and Business Overview
    Table 64. Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 65. Daiichi Sankyo Product
    Table 66. Daiichi Sankyo Recent Development
    Table 67. Eli Lilly Corporation Information
    Table 68. Eli Lilly Description and Business Overview
    Table 69. Eli Lilly Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 70. Eli Lilly Product
    Table 71. Eli Lilly Recent Development
    Table 72. Fast Forward Llc Corporation Information
    Table 73. Fast Forward Llc Description and Business Overview
    Table 74. Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 75. Fast Forward Llc Product
    Table 76. Fast Forward Llc Recent Development
    Table 77. Antisense Therapeutics Corporation Information
    Table 78. Antisense Therapeutics Description and Business Overview
    Table 79. Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 80. Antisense Therapeutics Product
    Table 81. Antisense Therapeutics Recent Development
    Table 82. Apitope Corporation Information
    Table 83. Apitope Description and Business Overview
    Table 84. Apitope Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 85. Apitope Product
    Table 86. Apitope Recent Development
    Table 87. Five Prime Therapeutics Corporation Information
    Table 88. Five Prime Therapeutics Description and Business Overview
    Table 89. Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 90. Five Prime Therapeutics Product
    Table 91. Five Prime Therapeutics Recent Development
    Table 92. Genmab Corporation Information
    Table 93. Genmab Description and Business Overview
    Table 94. Genmab Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 95. Genmab Product
    Table 96. Genmab Recent Development
    Table 97. Artielle Immunotherapeutics Corporation Information
    Table 98. Artielle Immunotherapeutics Description and Business Overview
    Table 99. Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 100. Artielle Immunotherapeutics Product
    Table 101. Artielle Immunotherapeutics Recent Development
    Table 102. Genzyme Corporation Information
    Table 103. Genzyme Description and Business Overview
    Table 104. Genzyme Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 105. Genzyme Product
    Table 106. Genzyme Recent Development
    Table 107. Glaxosmithkline Corporation Information
    Table 108. Glaxosmithkline Description and Business Overview
    Table 109. Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 110. Glaxosmithkline Product
    Table 111. Glaxosmithkline Recent Development
    Table 112. Gw Pharmaceuticals Corporation Information
    Table 113. Gw Pharmaceuticals Description and Business Overview
    Table 114. Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 115. Gw Pharmaceuticals Product
    Table 116. Gw Pharmaceuticals Recent Development
    Table 117. Innate Immunotherapeutics Corporation Information
    Table 118. Innate Immunotherapeutics Description and Business Overview
    Table 119. Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 120. Innate Immunotherapeutics Product
    Table 121. Innate Immunotherapeutics Recent Development
    Table 122. Key Raw Materials Lists
    Table 123. Raw Materials Key Suppliers Lists
    Table 124. Multiple Sclerosis (MS) Drugs Customers List
    Table 125. Multiple Sclerosis (MS) Drugs Distributors List
    Table 126. Research Programs/Design for This Report
    Table 127. Key Data Information from Secondary Sources
    Table 128. Key Data Information from Primary Sources
List of Figures
    Figure 1. Multiple Sclerosis (MS) Drugs Product Picture
    Figure 2. Global Multiple Sclerosis (MS) Drugs Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Multiple Sclerosis (MS) Drugs Market Size 2017-2028 (US$ Million)
    Figure 4. Global Multiple Sclerosis (MS) Drugs Sales 2017-2028 (K Pcs)
    Figure 5. United States Multiple Sclerosis (MS) Drugs Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 6. United States Multiple Sclerosis (MS) Drugs Market Size 2017-2028 (US$ Million)
    Figure 7. United States Multiple Sclerosis (MS) Drugs Sales 2017-2028 (K Pcs)
    Figure 8. United States Multiple Sclerosis (MS) Drugs Market Share in Global, in Value (US$ Million) 2017-2028
    Figure 9. United States Multiple Sclerosis (MS) Drugs Market Share in Global, in Volume (K Pcs) 2017-2028
    Figure 10. Multiple Sclerosis (MS) Drugs Report Years Considered
    Figure 11. Product Picture of Copaxone (Glatiramer Acetate, Copolymer 1)
    Figure 12. Product Picture of Novantrone (Mitoxantrone)
    Figure 13. Product Picture of Gilenya (Fingolimod, Fty720)
    Figure 14. Product Picture of Aubagio (Teriflunomide)
    Figure 15. Product Picture of Tecfidera (Dimethyl Fumarate)
    Figure 16. Product Picture of Firategrast (Sb683699, T-0047)
    Figure 17. Product Picture of Siponimod (Baf312)
    Figure 18. Product Picture of Others
    Figure 19. Global Multiple Sclerosis (MS) Drugs Market Share by Type in 2022 & 2028
    Figure 20. Global Multiple Sclerosis (MS) Drugs Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 21. Global Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Type (2017-2028)
    Figure 22. Global Multiple Sclerosis (MS) Drugs Sales by Type (2017-2028) & (K Pcs)
    Figure 23. Global Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Type (2017-2028)
    Figure 24. Global Multiple Sclerosis (MS) Drugs Price by Type (2017-2028) & (USD/Pcs)
    Figure 25. United States Multiple Sclerosis (MS) Drugs Market Share by Type in 2022 & 2028
    Figure 26. United States Multiple Sclerosis (MS) Drugs Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 27. United States Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Type (2017-2028)
    Figure 28. United States Multiple Sclerosis (MS) Drugs Sales by Type (2017-2028) & (K Pcs)
    Figure 29. United States Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Type (2017-2028)
    Figure 30. United States Multiple Sclerosis (MS) Drugs Price by Type (2017-2028) & (USD/Pcs)
    Figure 31. Product Picture of RRMS
    Figure 32. Product Picture of SPMS
    Figure 33. Product Picture of PPMS
    Figure 34. Product Picture of PRMS
    Figure 35. Global Multiple Sclerosis (MS) Drugs Market Share by Application in 2022 & 2028
    Figure 36. Global Multiple Sclerosis (MS) Drugs Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 37. Global Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Application (2017-2028)
    Figure 38. Global Multiple Sclerosis (MS) Drugs Sales by Application (2017-2028) & (K Pcs)
    Figure 39. Global Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Application (2017-2028)
    Figure 40. Global Multiple Sclerosis (MS) Drugs Price by Application (2017-2028) & (USD/Pcs)
    Figure 41. United States Multiple Sclerosis (MS) Drugs Market Share by Application in 2022 & 2028
    Figure 42. United States Multiple Sclerosis (MS) Drugs Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 43. United States Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Application (2017-2028)
    Figure 44. United States Multiple Sclerosis (MS) Drugs Sales by Application (2017-2028) & (K Pcs)
    Figure 45. United States Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Application (2017-2028)
    Figure 46. United States Multiple Sclerosis (MS) Drugs Price by Application (2017-2028) & (USD/Pcs)
    Figure 47. North America Multiple Sclerosis (MS) Drugs Sales in Volume Growth Rate 2017-2028 (K Pcs)
    Figure 48. North America Multiple Sclerosis (MS) Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 49. U.S. Multiple Sclerosis (MS) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 50. Canada Multiple Sclerosis (MS) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 51. Europe Multiple Sclerosis (MS) Drugs Sales in Volume Growth Rate 2017-2028 (K Pcs)
    Figure 52. Europe Multiple Sclerosis (MS) Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 53. Germany Multiple Sclerosis (MS) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 54. France Multiple Sclerosis (MS) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 55. U.K. Multiple Sclerosis (MS) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 56. Italy Multiple Sclerosis (MS) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 57. Russia Multiple Sclerosis (MS) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 58. Asia-Pacific Multiple Sclerosis (MS) Drugs Sales in Volume Growth Rate 2017-2028 (K Pcs)
    Figure 59. Asia-Pacific Multiple Sclerosis (MS) Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 60. China Multiple Sclerosis (MS) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 61. Japan Multiple Sclerosis (MS) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 62. South Korea Multiple Sclerosis (MS) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 63. India Multiple Sclerosis (MS) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 64. Australia Multiple Sclerosis (MS) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 65. Taiwan Multiple Sclerosis (MS) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 66. Indonesia Multiple Sclerosis (MS) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 67. Thailand Multiple Sclerosis (MS) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 68. Malaysia Multiple Sclerosis (MS) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 69. Philippines Multiple Sclerosis (MS) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 70. Latin America Multiple Sclerosis (MS) Drugs Sales in Volume Growth Rate 2017-2028 (K Pcs)
    Figure 71. Latin America Multiple Sclerosis (MS) Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 72. Mexico Multiple Sclerosis (MS) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 73. Brazil Multiple Sclerosis (MS) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 74. Argentina Multiple Sclerosis (MS) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 75. Middle East & Africa Multiple Sclerosis (MS) Drugs Sales in Volume Growth Rate 2017-2028 (K Pcs)
    Figure 76. Middle East & Africa Multiple Sclerosis (MS) Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 77. Turkey Multiple Sclerosis (MS) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 78. Saudi Arabia Multiple Sclerosis (MS) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 79. U.A.E Multiple Sclerosis (MS) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 80. Multiple Sclerosis (MS) Drugs Value Chain
    Figure 81. Multiple Sclerosis (MS) Drugs Production Process
    Figure 82. Channels of Distribution
    Figure 83. Distributors Profiles
    Figure 84. Bottom-up and Top-down Approaches for This Report
    Figure 85. Data Triangulation
    Figure 86. Key Executives Interviewed